Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec (Imatinib mesylate): 10 years' experience at Patan Hospital, Nepal

Gyan K. Kayastha, Nora Ranjitkar, Radha Gurung, Raj K. Kc, Sanjit Karki, Roshan Shrestha, Raj K. Thapa, Piyush Rajbhandari, Buddhi Poudyal, Paras Acharya, David J. Roberts, Bruce Hayes, Mark Zimmerman, Buddha Basnyat, Aaron Mansfield

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The Glivec International Patient Assistance Programme makes Glivec (Imatinib mesylate) available to Philadelphia chromosome/BCR-ABL1 positive patients with chronic myeloid leukaemia (CML) in Lower and Middle Income Countries (LMIC). We have established a large cohort of 211 CML patients who are eligible for Imatinib, in Kathmandu, Nepal. Thirty-one patients were lost to follow-up. We report on 180 CML patients with a median age of 38 years (range 9-81). Of these 180 patients, 162 underwent cytogenetic testing and 110 were investigated by reverse transcription polymerase chain reaction. One hundred and thirty-nine of the 180 patients (77·2%) had at least one optimal response. Taken together, our cohort has a 95% overall survival rate and 78% of the patients were still taking Glivec at a median time of 48·8 months (range 3-140 months). The number of patients who actually failed therapy, as defined by the LeukaemiaNet 2013 criteria, was 39 (21·7%). While our cohort has some differences with those in North America or Europe, we have shown Glivec is effective in inducing an optimal response in our patients in Nepal and that it is possible to deliver a clinical service for CML patients using tyrosine kinase inhibitors in resource-poor settings.

Original languageEnglish (US)
JournalBritish Journal of Haematology
DOIs
StateAccepted/In press - 2017

Fingerprint

Philadelphia Chromosome
Nepal
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib Mesylate
Lost to Follow-Up
North America
Cytogenetics
Protein-Tyrosine Kinases
Reverse Transcription
Survival Rate

Keywords

  • BCR-ABL1
  • Glivec (Imatinib mesylate)
  • Philadelphia chromosome

ASJC Scopus subject areas

  • Hematology

Cite this

Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec (Imatinib mesylate) : 10 years' experience at Patan Hospital, Nepal. / Kayastha, Gyan K.; Ranjitkar, Nora; Gurung, Radha; Kc, Raj K.; Karki, Sanjit; Shrestha, Roshan; Thapa, Raj K.; Rajbhandari, Piyush; Poudyal, Buddhi; Acharya, Paras; Roberts, David J.; Hayes, Bruce; Zimmerman, Mark; Basnyat, Buddha; Mansfield, Aaron.

In: British Journal of Haematology, 2017.

Research output: Contribution to journalArticle

Kayastha, GK, Ranjitkar, N, Gurung, R, Kc, RK, Karki, S, Shrestha, R, Thapa, RK, Rajbhandari, P, Poudyal, B, Acharya, P, Roberts, DJ, Hayes, B, Zimmerman, M, Basnyat, B & Mansfield, A 2017, 'Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec (Imatinib mesylate): 10 years' experience at Patan Hospital, Nepal', British Journal of Haematology. https://doi.org/10.1111/bjh.14645
Kayastha, Gyan K. ; Ranjitkar, Nora ; Gurung, Radha ; Kc, Raj K. ; Karki, Sanjit ; Shrestha, Roshan ; Thapa, Raj K. ; Rajbhandari, Piyush ; Poudyal, Buddhi ; Acharya, Paras ; Roberts, David J. ; Hayes, Bruce ; Zimmerman, Mark ; Basnyat, Buddha ; Mansfield, Aaron. / Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec (Imatinib mesylate) : 10 years' experience at Patan Hospital, Nepal. In: British Journal of Haematology. 2017.
@article{2f6732798a444510a1b43c29e64ef568,
title = "Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec (Imatinib mesylate): 10 years' experience at Patan Hospital, Nepal",
abstract = "The Glivec International Patient Assistance Programme makes Glivec (Imatinib mesylate) available to Philadelphia chromosome/BCR-ABL1 positive patients with chronic myeloid leukaemia (CML) in Lower and Middle Income Countries (LMIC). We have established a large cohort of 211 CML patients who are eligible for Imatinib, in Kathmandu, Nepal. Thirty-one patients were lost to follow-up. We report on 180 CML patients with a median age of 38 years (range 9-81). Of these 180 patients, 162 underwent cytogenetic testing and 110 were investigated by reverse transcription polymerase chain reaction. One hundred and thirty-nine of the 180 patients (77·2{\%}) had at least one optimal response. Taken together, our cohort has a 95{\%} overall survival rate and 78{\%} of the patients were still taking Glivec at a median time of 48·8 months (range 3-140 months). The number of patients who actually failed therapy, as defined by the LeukaemiaNet 2013 criteria, was 39 (21·7{\%}). While our cohort has some differences with those in North America or Europe, we have shown Glivec is effective in inducing an optimal response in our patients in Nepal and that it is possible to deliver a clinical service for CML patients using tyrosine kinase inhibitors in resource-poor settings.",
keywords = "BCR-ABL1, Glivec (Imatinib mesylate), Philadelphia chromosome",
author = "Kayastha, {Gyan K.} and Nora Ranjitkar and Radha Gurung and Kc, {Raj K.} and Sanjit Karki and Roshan Shrestha and Thapa, {Raj K.} and Piyush Rajbhandari and Buddhi Poudyal and Paras Acharya and Roberts, {David J.} and Bruce Hayes and Mark Zimmerman and Buddha Basnyat and Aaron Mansfield",
year = "2017",
doi = "10.1111/bjh.14645",
language = "English (US)",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec (Imatinib mesylate)

T2 - 10 years' experience at Patan Hospital, Nepal

AU - Kayastha, Gyan K.

AU - Ranjitkar, Nora

AU - Gurung, Radha

AU - Kc, Raj K.

AU - Karki, Sanjit

AU - Shrestha, Roshan

AU - Thapa, Raj K.

AU - Rajbhandari, Piyush

AU - Poudyal, Buddhi

AU - Acharya, Paras

AU - Roberts, David J.

AU - Hayes, Bruce

AU - Zimmerman, Mark

AU - Basnyat, Buddha

AU - Mansfield, Aaron

PY - 2017

Y1 - 2017

N2 - The Glivec International Patient Assistance Programme makes Glivec (Imatinib mesylate) available to Philadelphia chromosome/BCR-ABL1 positive patients with chronic myeloid leukaemia (CML) in Lower and Middle Income Countries (LMIC). We have established a large cohort of 211 CML patients who are eligible for Imatinib, in Kathmandu, Nepal. Thirty-one patients were lost to follow-up. We report on 180 CML patients with a median age of 38 years (range 9-81). Of these 180 patients, 162 underwent cytogenetic testing and 110 were investigated by reverse transcription polymerase chain reaction. One hundred and thirty-nine of the 180 patients (77·2%) had at least one optimal response. Taken together, our cohort has a 95% overall survival rate and 78% of the patients were still taking Glivec at a median time of 48·8 months (range 3-140 months). The number of patients who actually failed therapy, as defined by the LeukaemiaNet 2013 criteria, was 39 (21·7%). While our cohort has some differences with those in North America or Europe, we have shown Glivec is effective in inducing an optimal response in our patients in Nepal and that it is possible to deliver a clinical service for CML patients using tyrosine kinase inhibitors in resource-poor settings.

AB - The Glivec International Patient Assistance Programme makes Glivec (Imatinib mesylate) available to Philadelphia chromosome/BCR-ABL1 positive patients with chronic myeloid leukaemia (CML) in Lower and Middle Income Countries (LMIC). We have established a large cohort of 211 CML patients who are eligible for Imatinib, in Kathmandu, Nepal. Thirty-one patients were lost to follow-up. We report on 180 CML patients with a median age of 38 years (range 9-81). Of these 180 patients, 162 underwent cytogenetic testing and 110 were investigated by reverse transcription polymerase chain reaction. One hundred and thirty-nine of the 180 patients (77·2%) had at least one optimal response. Taken together, our cohort has a 95% overall survival rate and 78% of the patients were still taking Glivec at a median time of 48·8 months (range 3-140 months). The number of patients who actually failed therapy, as defined by the LeukaemiaNet 2013 criteria, was 39 (21·7%). While our cohort has some differences with those in North America or Europe, we have shown Glivec is effective in inducing an optimal response in our patients in Nepal and that it is possible to deliver a clinical service for CML patients using tyrosine kinase inhibitors in resource-poor settings.

KW - BCR-ABL1

KW - Glivec (Imatinib mesylate)

KW - Philadelphia chromosome

UR - http://www.scopus.com/inward/record.url?scp=85016558897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016558897&partnerID=8YFLogxK

U2 - 10.1111/bjh.14645

DO - 10.1111/bjh.14645

M3 - Article

C2 - 28369812

AN - SCOPUS:85016558897

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

ER -